Akers Biosciences, Inc. Issue of Equity (7349T)

TIDMAKR

RNS Number : 7349T

Akers Biosciences, Inc.

10 January 2017

10 January 2017

This announcement contains inside information

Akers Biosciences, Inc.

Filing of Supplement to Form S-3 Registration Statement

Issue of Equity

Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers Bio" or the "Company"), a developer of rapid health information technologies, announces that the Company will file a further supplement to its Form S-3 Registration Statement confirming a fully underwritten sale of 1,667,000 common shares at a public offering price of $1.20 per share (the "Offering") together with the issuance of 833,500 five-year warrants to purchase common shares with an exercise price of $1.50 (the "Warrants"). The gross proceeds from the Offering, excluding any proceeds on the exercise of the Warrants, are expected to be approximately $2,000,400, before deducting the underwriting discount and estimated offering expenses. The funds raised will be used for working capital as well as to accelerate growth in the US and in international markets, further develop new customers and launch new diagnostic products.

The Offering is expected to close on January 13, 2017, subject to satisfaction of customary closing conditions. The shares and warrants are being offered by Akers Biosciences, Inc. pursuant to a registration statement previously filed with and subsequently declared effective by the Securities and Exchange Commission. A prospectus supplement relating to the Offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov as well as the Company's website at www.akersbio.com.

The Company has applied for the admission of the Offering shares to AIM and this is expected to take place on January 13, 2017 ("Admission"). Following Admission, the Company's issued share capital will consist of 7,119,545 common shares with no common shares held in treasury. Therefore, the above figure of 7,119,545 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

Joseph Gunnar & Co., LLC is acting as sole book-running manager for the offering.

This announcement shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Copies of the prospectus supplement and accompanying base prospectus relating to the Offering may be obtained from Joseph Gunnar & Co, LLC, Prospectus Department, 30 Broad Street, 11th Floor, New York, NY 10004, telephone: [phone], email: [e-mail].

About Akers Biosciences, Inc.

Akers Bio develops, manufactures, and supplies rapid screening and testing products designed to deliver quicker and more cost-effective healthcare information to healthcare providers and consumers. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. The Company has aligned with major healthcare companies and high volume medical product distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics.

Additional information on the Company and its products can be found at www.akersbio.com. Follow us on Twitter @AkersBio.

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

Cautionary Statement Regarding Forward Looking Statements

Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements reflect the Company's expectations about its future operating results, performance and opportunities that involve substantial risks and uncertainties. These statements include but are not limited to statements regarding the intended terms of the offering, closing of the offering and use of any proceeds from the offering. When used herein, the words "anticipate," "believe," "estimate," "upcoming," "plan," "target", "intend" and "expect" and similar expressions, as they relate to Akers Biosciences, Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company's actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.

For more information:

Akers Biosciences, Inc.

John J. Gormally, Chief Executive Officer

Raymond F. Akers, Jr. PhD, Co-founder and Chief Scientific Director

Tel. [phone]

Taglich Brothers, Inc. (Investor Relations)

Chris Schreiber

Tel. [phone]

Email: [e-mail]

finnCap (UK Nominated Adviser and Broker)

Adrian Hargrave / Scott Mathieson (Corporate Finance)

Steve Norcross (Broking)

Tel. [phone]

Vigo Communications (Global Public Relations)

Ben Simons / Fiona Henson

Tel. [phone]

Email: [e-mail]

This information is provided by RNS

The company news service from the London Stock Exchange

END

IOEOKKDDDBKKFDD

(END) Dow Jones Newswires

January 10, 2017 02:00 ET (07:00 GMT)